Navigation Links
Unique nerve-stimulation treatment proves effective against drug-resistant epilepsy
Date:5/25/2011

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients estimated to be as many as 1 million in the U.S. drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

But at an epilepsy conference last month, Dr. Christopher DeGiorgio, a UCLA professor of neurology, presented the results of a non-invasive, non-pharmaceutical treatment that shows promise in controlling seizures.

In his talk at the Antiepileptic Drug Trials XI Conference in Miami, Fla., DeGiorgio reported the results of a Phase 2 clinical trial of a new treatment called trigeminal nerve stimulation (TNS). He noted that 40 percent of the patients receiving TNS treatment experienced a significant improvement in seizure reduction.

The external stimulator, which is about the size of a large cell phone, attaches to a belt or can slip into a pocket. Wires from the stimulator are passed under the clothing and connected to conductive pads attached to the forehead. The electrodes, which can be covered by a cap or scarf, transmit a signal to the trigeminal nerve, which extends into the brain from the face and forehead and is known to play a role in seizure inhibition.

"TNS offers potential benefits it can be delivered bilaterally (to both sides of the brain) and at high frequencies," DeGiorgio said. "Since the electrical energy does not travel directly into the brain, TNS provides a safe method of brain modulation."

The clinical trial showed that at the end of the 18-week study, 40 percent of patients receiving TNS experienced a significant improvement in seizure reduction, which is defined as a 50 percent or greater decrease in the frequency of seizures.

"We showed that TNS works well, under stringent clinical-trial conditions. The fact that 40 percent showed a clinically-meaningful response is exciting," DeGiorgio said.

These results confirm and extend the findings of DeGiorgio's positive Phase 1 trial in epilepsy, reported in 2009 in the journal Neurology.

In addition, the researchers found that the TNS treatment also improved the mood of the participants. Since depression is a common problem in people with epilepsy, this finding could have significant impact on the quality of life of people who suffer from the disorder.

DeGiorgio, lead inventor of TNS, was the principal investigator for the Phase 2 study, which was conducted at Olive ViewUCLA Medical Center and the University of Southern California.

"I'm encouraged to see that our non-invasive and safe approach to neuromodulation compares favorably to pharmaceutical and surgically implanteddevice therapies of drug-resistant epilepsy," he said.


'/>"/>

Contact: Mark Wheeler
mwheeler@mednet.ucla.edu
310-794-2265
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Stem cell technology used in unique surgery
2. Unique AED pads give hearts a second chance
3. Research shows that some features of human face perception are not uniquely human
4. Emory Healthcares unique training shows signific knowledge of quality principles
5. Treating newborn horses: A unique form of pediatrics
6. Most Breast Tumors Have Unique Genetic Fingerprint, Study Finds
7. Pilot study examines stress, anxiety and needs of young women with a unique breast cancer
8. Bird embryo provides unique insights into development related to cancer and wound healing
9. Conference highlights UC Berkeleys unique approach to green chemistry
10. Unique case study on Alzheimers disease
11. Womens unique connection to nature is explored in special issue of Ecopsychology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... Ultimate ... K-20 Education Summit to be held March 23-25, 2017 in Tampa, and reminded ... 2017. , The keynote speakers include Dr. Michelle R. Weise, executive director of ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... Sharon Kleyne, ... the air to educate listeners about the benefits of making new water infrastructure a ... Kleyne said, “it’s appropriate that we expect water infrastructure to become a top priority ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... today it has earned organic certification under the USDA National Organic Program (NOP) ... Organic Certification process, we have established organic production and handling systems to complement ...
(Date:1/23/2017)... ... ... at the Mill”: a story of love and redemption, hope and uncertainty as a ... , “The Inn at the Mill” is the creation of published author, Lois Kulp, ... now living in Berks County on Crow Hill. The inn, the mill and ...
(Date:1/23/2017)... Atlanta, Georgia (PRWEB) , ... January 23, 2017 , ... Valentine’s Day is a time ... to their loved ones. For those who may be looking for the ideal present, Atlanta-based ... gift certificate and get an additional $25 free. Or, spend $200 and get $50 free. ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... 20, 2017 ResMed (NYSE: RMD ), BMC ... Winter Haven, Florida ) today announced they have agreed on ... 3B will be permitted to sell their existing products in exchange ... settlement payment to 3B to close the Florida ... an admission of liability or wrongdoing by any party. ...
(Date:1/21/2017)... , Jan. 20, 2017  Today, during ... Conference, "PI3K Pathways in Immunology, Growth Disorders ... (NASDAQ: INFI ) presented preclinical ... candidate that selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). Preclinical ... help overcome resistance to checkpoint inhibition by ...
(Date:1/20/2017)... -- Research and Markets has announced the addition ... BMP, BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver ... - 2024" report to their offering. ... The global clinical laboratory testing market ... Introduction of innovative solutions on the grounds of maximum efficiency and ...
Breaking Medicine Technology: